Retatrutide
LY3437943 · triple agonist
An investigational triple-agonist. Not an everyday starter.
A triple incretin/glucagon agonist in late-stage trials with very large weight-loss signals. Not approved. Doses below are trial-range education only.
Usual range
1–12 mg
Schedule
Once weekly (trial-style)
Half-life
~6 days
How it is used
Investigational GIP/GLP-1/glucagon triple agonist.
Subcutaneous
Weekly, consistent day.
Trial durations were months, always titrated.
How to mix this vial
Typical vial 10 mg · 2 mL BAC
Research vials vary. Example: 10 mg + 2 mL → 5 mg/mL.
Fridge, research handling.
Side effects
- GI effects
- Elevated heart rate
- Lean-mass loss
- Unknown long-term profile
Who should skip this
- Pregnancy
- MTC/MEN2 (class caution)
- Unsupervised research use
Nutrition note
Same GLP-1 kitchen: small, bland, protein-first. Watch resting heart rate.
Not approved. Peptipedia lists trial-range figures so the titration idea is visible — not so you can source it.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.